Mediwelcome Healthcare Management & Technology Inc. (2159) AI Stock Analysis

• Market Cap: HK$336.00M
• Dividend Yield: N/A
• Average Volume (3M): 223.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: -5.38%
• EPS Growth: 63.93%
• Country: HK
• Employees: 311
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.03
• Shares Outstanding: 280,000,000
• 10 Day Avg. Volume: 175,360
• 30 Day Avg. Volume: 223,333
• PEG Ratio: 0.04
• Price to Book (P/B): 1.31
• Price to Sales (P/S): 0.29
• P/FCF Ratio: -3.45
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: HK$1.00 ▼(-19.35% Downside)

The overall stock score is primarily impacted by financial performance challenges, including declining revenues and cash flow issues. Technical analysis provides mixed signals, with bearish momentum but neutral RSI and Stochastic indicators. Valuation is unattractive due to negative earnings and lack of dividends.

Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model

Company Description

Mediwelcome Healthcare Management & Technology Inc. (2159) is a company operating in the healthcare sector, primarily focusing on providing comprehensive healthcare management and technology solutions. The company specializes in offering services such as medical conference management, hospital management consulting, and digital marketing solutions for healthcare institutions. Mediwelcome aims to enhance hospital operations and improve patient care through its innovative technology offerings and expert consultancy services.

How the Company Makes Money

Mediwelcome Healthcare Management & Technology Inc. generates revenue through several key streams. The primary sources of income include fees from managing and organizing medical conferences and events, which serve as significant platforms for knowledge sharing and networking within the healthcare industry. Additionally, the company earns from providing consulting services to hospitals, which involves advising on operational improvements and management strategies. Another revenue stream comes from digital marketing solutions tailored for healthcare providers, aimed at boosting their visibility and patient engagement. Partnerships with healthcare institutions and continuous innovation in service offerings also play a critical role in driving the company's earnings.

Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview

Summary

Mediwelcome Healthcare Management & Technology Inc. faces financial challenges with declining revenues and persistent losses. While there are some positive signs in cost management and moderate leverage, the company's cash flow issues and decreasing equity base present significant risks.

Income Statement

The company's revenue has been declining, with a significant drop from 2021 to 2024. The EBIT and net income margins are negative, indicating operational challenges and losses. However, there is a slight improvement in gross profit margin from 2023 to 2024, suggesting some cost management progress.

Balance Sheet

The company has maintained positive stockholders' equity, though it has declined over recent years. The debt-to-equity ratio remains moderate, showing some leverage but not excessively risky. The equity ratio is decreasing, indicating lower asset financing through equity, which could pose a risk if liabilities increase.

Cash Flow

The company struggles with cash flow, with negative operating and free cash flows in recent years. The operating cash flow to net income ratio is not meaningful due to negative values, presenting challenges in cash generation. Although there was a significant capital expenditure reduction, it wasn't enough to offset cash flow deficits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	307.94M	321.56M	331.31M	323.37M	708.36M	432.29M
Gross Profit	52.10M	51.00M	29.89M	32.55M	93.60M	96.31M
EBITDA	-14.94M	-33.61M	-74.53M	-69.08M	11.32M	41.06M
Net Income	-29.16M	-45.24M	-94.10M	-89.20M	4.64M	21.04M
Balance Sheet
Total Assets	219.14M	194.09M	214.32M	317.83M	366.70M	280.08M
Cash, Cash Equivalents and Short-Term Investments	94.24M	71.66M	80.35M	154.02M	174.83M	104.89M
Total Debt	49.38M	47.73M	31.13M	26.48M	25.18M	25.43M
Total Liabilities	150.73M	120.81M	94.35M	116.97M	73.21M	109.08M
Stockholders Equity	64.23M	71.14M	116.13M	195.02M	283.11M	161.18M
Cash Flow
Free Cash Flow	10.32M	-27.10M	-77.18M	-22.75M	-24.73M	17.31M
Operating Cash Flow	10.47M	-14.05M	-75.58M	-18.46M	262.00K	31.12M
Investing Cash Flow	-9.88M	-326.00K	16.46M	-8.36M	-16.77M	-10.98M
Financing Cash Flow	11.22M	5.68M	906.00K	54.00K	92.84M	-4.79M

Mediwelcome Healthcare Management & Technology Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Negative. The current price of 1.24 is above the 20-day moving average (MA) of 1.21, below the 50-day MA of 1.32, and above the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of 52.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2159.

Mediwelcome Healthcare Management & Technology Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0401	55 Neutral	HK$86.83M	-13.14	-9.43%	―	-10.71%	83.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9686	48 Neutral	HK$799.78M	-10.25	-20.43%	―	―	―
2159	46 Neutral	HK$336.00M	―	-35.99%	―	-5.38%	63.93%
2138	46 Neutral	HK$770.39M	-4.54	-8.91%	1.56%	-1.68%	-781.88%
2158	41 Neutral	HK$5.08B	―	-2.97%	―	-12.31%	41.72%
2251	40 Neutral	HK$1.17B	-6.35	-12.97%	―	-32.17%	-1.20%

Mediwelcome Healthcare Management & Technology Inc. Corporate Events

Mediwelcome Announces Key Executive and Board Changes

Mediwelcome Healthcare Management & Technology Inc. announced significant changes in its executive team and board committees, effective from September 1, 2025. Ms. Liu Guijin and Mr. Yang Xiaoxi have resigned from their respective positions due to personal commitments, while Ms. Deng Chengying and Mr. Chen Huilin have been appointed to key roles. These changes are aimed at strengthening the company’s leadership and ensuring continued compliance and strategic management, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (HK:2159) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Mediwelcome Healthcare Management & Technology Inc. stock, see the HK:2159 Stock Forecast page.

Mediwelcome Announces Board Composition and Roles

Mediwelcome Healthcare Management & Technology Inc. has announced the composition of its board of directors and their roles within the company. The announcement details the executive, non-executive, and independent non-executive directors, along with their respective positions on the company’s audit, remuneration, and nomination committees. This update may impact the company’s governance and strategic direction, potentially influencing stakeholder confidence and market perception.

The most recent analyst rating on (HK:2159) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Mediwelcome Healthcare Management & Technology Inc. stock, see the HK:2159 Stock Forecast page.

Mediwelcome Reports Improved Interim Financial Results Amid Revenue Decline

Mediwelcome Healthcare Management & Technology Inc. announced its unaudited consolidated interim results for the six months ending June 30, 2025. The company reported a decrease in revenue from RMB 140,670,000 in 2024 to RMB 127,052,000 in 2025, with a reduced net loss of RMB 4,086,000 compared to RMB 22,929,000 in the previous year. This improvement in financial performance is attributed to lower administrative and research expenses, despite a decline in revenue, indicating a strategic focus on cost management.

The most recent analyst rating on (HK:2159) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Mediwelcome Healthcare Management & Technology Inc. stock, see the HK:2159 Stock Forecast page.

Mediwelcome Schedules Board Meeting to Review Interim Results

Mediwelcome Healthcare Management & Technology Inc. has announced a board meeting scheduled for August 28, 2025, to discuss and approve the interim results for the six months ended June 30, 2025. The meeting will also consider the payment of an interim dividend and other business matters, potentially impacting the company’s financial strategy and shareholder returns.

Mediwelcome Reports Significant Reduction in Losses for H1 2025

Mediwelcome Healthcare Management & Technology Inc. announced a significant reduction in its losses for the first half of 2025, with an approximate 82.2% decrease in loss compared to the same period in 2024. This improvement is attributed to increased gross profit from focusing on higher-margin projects and reduced expenses in research, development, and administration, indicating a positive shift in the company’s financial health.

Mediwelcome Completes Share Placement to Fund AI Medical Innovations

Mediwelcome Healthcare Management & Technology Inc. has successfully completed the placing of 40 million new shares, raising approximately HK$21.32 million in net proceeds. The funds will be allocated towards the company’s AI medical vertical model development, specifically for recruiting AI talent, purchasing specialized medical models, and ensuring data compliance. This strategic move aims to enhance Mediwelcome’s position in the healthcare technology sector by bolstering its innovative capabilities in AI-driven medical solutions.